HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 195 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,636,669 | +4.1% | 31,258 | -19.2% | 0.00% | 0.0% |
Q1 2024 | $1,572,770 | +15.4% | 38,662 | +4.9% | 0.00% | 0.0% |
Q4 2023 | $1,362,641 | +9.4% | 36,868 | +13.0% | 0.00% | 0.0% |
Q3 2023 | $1,246,046 | +2.9% | 32,619 | -2.9% | 0.00% | 0.0% |
Q2 2023 | $1,211,266 | -4.2% | 33,581 | +1.4% | 0.00% | 0.0% |
Q1 2023 | $1,264,242 | -42.6% | 33,104 | -14.5% | 0.00% | -50.0% |
Q4 2022 | $2,202,030 | +53.6% | 38,700 | +6.8% | 0.01% | +33.3% |
Q3 2022 | $1,434,000 | -9.0% | 36,252 | +1.2% | 0.01% | +20.0% |
Q2 2022 | $1,576,000 | -27.1% | 35,829 | -33.9% | 0.01% | 0.0% |
Q1 2022 | $2,161,000 | -18.9% | 54,218 | -18.2% | 0.01% | 0.0% |
Q4 2021 | $2,666,000 | +6.3% | 66,315 | +7.5% | 0.01% | -28.6% |
Q3 2021 | $2,508,000 | -23.6% | 61,664 | -14.7% | 0.01% | -30.0% |
Q2 2021 | $3,281,000 | +22.9% | 72,257 | +12.8% | 0.01% | +25.0% |
Q1 2021 | $2,670,000 | +3.7% | 64,037 | +6.2% | 0.01% | -20.0% |
Q4 2020 | $2,574,000 | +152.8% | 60,274 | +55.6% | 0.01% | +100.0% |
Q3 2020 | $1,018,000 | -5.5% | 38,731 | -3.6% | 0.01% | -16.7% |
Q2 2020 | $1,077,000 | +113.3% | 40,160 | +43.2% | 0.01% | +50.0% |
Q1 2020 | $505,000 | -44.3% | 28,044 | -45.1% | 0.00% | 0.0% |
Q4 2019 | $906,000 | +4.5% | 51,093 | -8.6% | 0.00% | -20.0% |
Q3 2019 | $867,000 | -9.4% | 55,909 | +0.4% | 0.01% | -16.7% |
Q2 2019 | $957,000 | -5.4% | 55,688 | -11.4% | 0.01% | 0.0% |
Q1 2019 | $1,012,000 | +11.3% | 62,835 | +1.2% | 0.01% | 0.0% |
Q4 2018 | $909,000 | -32.5% | 62,119 | -16.2% | 0.01% | -33.3% |
Q3 2018 | $1,347,000 | +3.8% | 74,111 | -3.7% | 0.01% | 0.0% |
Q2 2018 | $1,298,000 | -18.6% | 76,939 | -5.5% | 0.01% | -10.0% |
Q1 2018 | $1,595,000 | -16.6% | 81,407 | -13.8% | 0.01% | -23.1% |
Q4 2017 | $1,913,000 | +25.0% | 94,410 | +7.1% | 0.01% | -7.1% |
Q3 2017 | $1,531,000 | +45.3% | 88,134 | +7.2% | 0.01% | +27.3% |
Q2 2017 | $1,054,000 | -0.6% | 82,187 | +0.5% | 0.01% | 0.0% |
Q1 2017 | $1,060,000 | +4.1% | 81,813 | -20.6% | 0.01% | 0.0% |
Q4 2016 | $1,018,000 | -10.5% | 103,060 | +9.5% | 0.01% | -31.2% |
Q3 2016 | $1,137,000 | +16.5% | 94,137 | -16.8% | 0.02% | +23.1% |
Q2 2016 | $976,000 | -7.0% | 113,149 | +2.0% | 0.01% | -7.1% |
Q1 2016 | $1,050,000 | -50.5% | 110,885 | -9.5% | 0.01% | -46.2% |
Q4 2015 | $2,123,000 | +41.7% | 122,509 | +9.8% | 0.03% | +23.8% |
Q3 2015 | $1,498,000 | -42.3% | 111,572 | -3.0% | 0.02% | -41.7% |
Q2 2015 | $2,598,000 | +50.3% | 115,069 | -4.9% | 0.04% | +80.0% |
Q1 2015 | $1,728,000 | +70.1% | 120,997 | +15.0% | 0.02% | +66.7% |
Q4 2014 | $1,016,000 | +5.7% | 105,242 | -0.4% | 0.01% | -7.7% |
Q3 2014 | $961,000 | -22.8% | 105,637 | -16.1% | 0.01% | -18.8% |
Q2 2014 | $1,245,000 | -49.1% | 125,979 | -34.6% | 0.02% | -48.4% |
Q1 2014 | $2,446,000 | +188.1% | 192,565 | +240.0% | 0.03% | +138.5% |
Q4 2013 | $849,000 | -19.8% | 56,644 | -40.9% | 0.01% | -48.0% |
Q3 2013 | $1,059,000 | +66.8% | 95,904 | +19.9% | 0.02% | +108.3% |
Q2 2013 | $635,000 | – | 79,979 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 14,092,771 | $206,177,000 | 28.12% |
BB BIOTECH AG | 8,322,860 | $121,763,000 | 3.90% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 398,633 | $4,579,000 | 2.84% |
DOHENY ASSET MANAGEMENT /CA | 227,193 | $3,324,000 | 2.43% |
SNYDER CAPITAL MANAGEMENT L P | 2,833,759 | $41,458,000 | 2.24% |
First Light Asset Management, LLC | 938,399 | $13,729,000 | 2.19% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 9,027,164 | $132,067,000 | 1.77% |
Taylor Wealth Management Partners | 204,277 | $2,989,000 | 1.72% |
Sterling Global Strategies LLC | 22,000 | $321,860,000 | 1.63% |
Granite Investment Partners, LLC | 988,939 | $14,468,000 | 1.06% |